Datascope Patient Monitors Revenue and Competitors
Estimated Revenue & Valuation
- Datascope Patient Monitors's estimated annual revenue is currently $7.8M per year.
- Datascope Patient Monitors's estimated revenue per employee is $251,000
Employee Data
- Datascope Patient Monitors has 31 Employees.
- Datascope Patient Monitors grew their employee count by 7% last year.
Datascope Patient Monitors's People
Name | Title | Email/Phone |
---|
Datascope Patient Monitors Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Datascope Patient Monitors?
Mindray was founded in 1991 in Shenzhen, China, with a mission to deliver high-quality, competitively priced medical devices to make healthcare more accessible and affordable around the world. Over the last 17 years, we have become a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence. According to Frost & Sullivan, in 2006 we attained leading market share in China both by units sold and revenue for the sale of patient monitoring devices. In addition to patient monitoring devices, we also believe that we hold leading market share in China in three part differentiation hematology analyzer, biochemistry analyzer and grayscale ultrasound imaging system segments.
keywords:N/AN/A
Total Funding
31
Number of Employees
$7.8M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.7M | 31 | 7% | N/A |
#2 | $3.6M | 31 | -14% | N/A |
#3 | $4.5M | 31 | -14% | N/A |
#4 | $6.7M | 31 | -11% | N/A |
#5 | $6.7M | 31 | 3% | N/A |